{"doi":"10.1111/aor.14942","title":"Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices","abstract":"BACKGROUND: GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is limited. OBJECTIVES: To assess the safety and efficacy of GLP-1 RA in durable LVAD patients. METHODS: We conducted a single-center retrospective analysis of patients on durable LVAD support treated with GLP-1 RA. Outcomes included cardiometabolic efficacy and LVAD and GLP-1 RA related adverse events up to 1 year post GLP-1 RA initiation. RESULTS: Forty LVAD patients were treated with GLP-1 RA therapy between 2018 and 2023. At 1 year follow-up, the patient's weight was significantly reduced (116 (98-134) vs. 110 (91-129) kg, p-value < 0.001), HBA1C was improved (6.4 (5.8-8.1) vs. 5.7 (5.3-6.1), p-value 0.003), and NT-proBNP levels were significantly reduced (810 (594-1413) vs. 732 (354-1155) pg/mL, p-value 0.04). GLP-1 RA therapy was not associated with cannula position change (cannula coronal angle of 29.7° (15.0-42.0) vs. 23.1° (12.8-42.3), p-value 0.683), and LVADs complication rate was relatively low (12.5% of the patients had hemocompatibility adverse events, 15% had driveline infection, 12% had HF hospitalization, and 2.5% (1 patient) died due to HeartMate2 malfunction). There was no interruption of drug administration due to adverse events. CONCLUSION: Durable LVAD patients treated with GLP-1 RA had improved cardiometabolic profiles and low major adverse events. GLP-1 RA therapy holds promise as a potential adjunctive treatment strategy in LVAD recipients, offering improved cardiometabolic profile, hemodynamics, and potential future transplant candidacy.","journal":"Artificial Organs","year":2025,"id":522592,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9584,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":947358,"name":"Changhee Lee","orcid":"0000-0002-8681-4739","position":1,"is_corresponding":false},{"id":1385834,"name":"Afsana Rahman","orcid":"0000-0002-2294-8690","position":2,"is_corresponding":false},{"id":1394094,"name":"Wojciech Rzechorzek","orcid":"0000-0002-9755-0580","position":3,"is_corresponding":false},{"id":260663,"name":"Ersilia M. DeFilippis","orcid":"0000-0002-0493-1326","position":4,"is_corresponding":false},{"id":1087407,"name":"Dor Lotan","orcid":"0000-0003-3501-6259","position":5,"is_corresponding":false},{"id":1394755,"name":"Cathrine M Moeller","orcid":null,"position":6,"is_corresponding":false},{"id":1253806,"name":"A. Fernandez Valledor","orcid":"0000-0002-6776-8079","position":7,"is_corresponding":false},{"id":1095843,"name":"Salwa Rahman","orcid":"0000-0002-2123-3845","position":8,"is_corresponding":false},{"id":1254390,"name":"Julia Baranowska","orcid":null,"position":9,"is_corresponding":false},{"id":281842,"name":"Kevin J. Clerkin","orcid":"0000-0001-8351-9219","position":10,"is_corresponding":false},{"id":264040,"name":"J. Fried","orcid":"0000-0001-6146-2637","position":11,"is_corresponding":false},{"id":1386307,"name":"Adil Yunis","orcid":null,"position":12,"is_corresponding":false},{"id":271769,"name":"M. Yuzefpolskaya","orcid":"0000-0003-4729-8943","position":13,"is_corresponding":false},{"id":271781,"name":"P.C. Colombo","orcid":"0000-0003-4977-3285","position":14,"is_corresponding":false},{"id":950007,"name":"Yuji Kaku","orcid":"0000-0002-1366-1129","position":15,"is_corresponding":false},{"id":199064,"name":"Yoshifumi Naka","orcid":null,"position":16,"is_corresponding":false},{"id":264041,"name":"Koji Takeda","orcid":"0000-0001-8263-1911","position":17,"is_corresponding":false},{"id":281839,"name":"J. Raikhelkar","orcid":"0000-0002-8561-7899","position":18,"is_corresponding":false},{"id":264043,"name":"Gabriel Sayer","orcid":"0000-0003-1701-1593","position":19,"is_corresponding":false},{"id":104009,"name":"Nir Uriel","orcid":"0000-0003-2301-3587","position":20,"is_corresponding":false},{"id":1253807,"name":"B. Elad","orcid":"0000-0001-9253-2351","position":0,"is_corresponding":true}],"reference_count":20,"raw_metadata":null,"created_at":"2026-07-19T02:49:54.058858Z","pmid":"39835590","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}